|*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions. |
Improvement of Multimodality Treatment Results for Advanced Pancreas Cancer
Olga L. Procopchuk, Vladimir S. Zemskov, Yaroslav M. Susak, Sergei V. Zemskov, Yuriy Y. Hodysh, Marina V. Zemskova, Wassil M. Nowicky, Bogomolets National Medical University, Kyiv, Ukraine; Kyiv Center of Liver, Pancreas and Bile Ducts Surgery, Kyiv, Ukraine; Ukrainian Anti-Cancer Institute, Vienna, Austria.
Currently there is no satisfactory treatment for pancreas cancer. The 12-month survival rate is approximately 18% for patients treated with gemcitabine and only around 2% for patients treated with 5-fluorouracil. In a recent study of 126 patients treated with gemcitabine or 5-fluorouracil, no patient survived beyond 19 months. The aim of this study was to investigate the activity and toxicity of Ukrain in the treatment of pancreas cancer. Between 01.01.1996 and 31.12.1999 forty two patients with stage II-IV pancreas cancer who refused chemotherapy were assigned to receive after surgery either vitamin C 5.4 g every second day x 10 and Ukrain 10 mg every second day x 10 (21 patients), or to vitamin C 5.4 g every second day x 10 and normal saline 10 mL (control group, 21 patients). The measures of efficacy were overall survival, body weight change, pain intensity (measured by analgesic consumption), Karnofsky performance status, and tumor response. 12-month survival was 81% in the Ukrain group compared to 14% in the control group, and 19-month survival was 48% in the Ukrain group compared to 5% in the control group. Both pain and Karnofsky status improved in ten Ukrain patients. Three Ukrain patients had an improvement in pain and no worsening of Karnofsky performance status. The longest survival in the Ukrain group was 50 months after the start of therapy (from January 1996 to March 2000). Median survival duration was 17.17 months for Ukrain treated patients and 6.97 months for the control group (p=0.05). Three Ukrain patients (14.3%) achieved partial tumour response with median duration of 14 months, 9 patients (42.9%) had stable disease for 13 months (median value). Ukrain treatment was well tolerated. Blood and urine examinations revealed no negative or toxic influence of Ukrain, and moreover, showed an improvement in the immune profile in Ukrain treated patients. We conclude that Ukrain not only improves the quality of life of pancreas cancer patients, but also prolongs survival in this disease. Whether and to what extent this drug can be used as standard therapy in pancreas cancer should be the object of a phase III study.
Here is a link to some background information on the Ukrain treatment. http://www.ralphmoss.com/ukrain.html
Reply to this message | Return to Main Message List